Search Results - "TAUER, Kurt W"

Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2―Negative Advanced Breast Cancer That Progressed during or after Bevacizumab by SCHWARTZBERG, Lee S, TAUER, Kurt W, BELL-MCGUINN, Katherine, KIRSHNER, Jeffrey J, EISENBERG, Peter, EMANUELSON, Richard, KEATON, Mark, LEVINE, Ellis, MEDGYESY, Diana C, QAMAR, Rubina, STARR, Alexander, SUNHEE KWON RO, HERMANN, Robert C, LOKKER, Nathalie A, HUDIS, Clifford A, MAKARI-JUDSON, Grace, ISAACS, Claudine, THADDEUS BECK, J, KAKLAMANI, Virginia, STEPANSKI, Edward J, RUGO, Hope S, WEI WANG

“…We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed…”
Get full text

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer by West, W H, Tauer, K W, Yannelli, J R, Marshall, G D, Orr, D W, Thurman, G B, Oldham, R K

“…Adoptive immunotherapy involving bolus-dose recombinant interleukin-2 (rIL-2) has been reported to induce tumor regression in some patients with cancer, but…”
Get more information

Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors by Stewart, Clinton F., Tagen, Michael, Schwartzberg, Lee S., Blakely, L. Johnetta, Tauer, Kurt W., Smiley, Linda M.

“…Purpose Topotecan is widely used for refractory solid tumors but multi-drug resistance may occur due to tumor expression of ATP-binding cassette (ABC)…”
Get full text

Experiencing neutropenia: quality of life interviews with adult cancer patients by Fortner, Barry V, Tauer, Kurt W, Okon, Ted, Houts, Arthur C, Schwartzberg, Lee S

“…Neutropenia is a common toxicity in chemotherapy but detailed information about how neutropenia is associated with changes in patients' quality of life is not…”
Get full text

Clinical pathway creation and adherence at a large hybrid cancer center by Carnell, Matthew, Fleming, Martin D., Portnoy, David Craig, Ballo, Matthew T., Fisher, Kristopher, Somer, Bradley G., Tauer, Kurt W., Prince, Cheryl A., Vanderwalde, Ari M.

“…Abstract only 298 Background: Clinical pathways are valuable in reducing treatment variation, improving outcomes, and reducing costs in an oncology setting…”
Get full text

Phase I/II study of neoadjuvant eribulin mesylate, carboplatin, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer by Schwartzberg, Lee Steven, Tauer, Kurt W., Hermann, Robert C., Nikolinakos, Petros G., Houts, Arthur C.

“…Abstract only…”
Get full text

Phase I/II study of neoadjuvant carboplatin, eribulin mesylate, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer by Schwartzberg, Lee Steven, Tauer, Kurt W., Hermann, Robert C., Nikolinakos, Petros G., Houts, Arthur C.

“…Abstract only TPS659 Background: Carboplatin, docetaxel and trastuzumab (TCH) regimen yields substantial pathologic complete response (pCR) in operable HER2+…”
Get full text

Relationship of grade to prognosis in localized primary angiosarcoma of the breast (PAOB) by Pandey, Manjari, Sutton, Gregory Ryan, Portnoy, David Craig, Tauer, Kurt W., Schwartzberg, Lee Steven, Dickson, Paxton, Martin, Michael Gary

“…Abstract only…”
Get full text

The Memphis breast cancer disparity-screening program by Vidal, Gregory A., Green, Zaquishia, Tankersley, Cynthia, Hidinger, Zachary, Miranda, Rafael, Baker, Bobby, Jacobson, Paula, Lamar, Kimberly, Rafalski, Edward, Tauer, Kurt W.

“…Abstract only…”
Get full text

For love of the profession. Kurt W. Tauer--Physician Executive of the Year Award by Tauer, Kurt W

Get more information

Effect of rituximab on outcomes in gastric B-cell lymphomas and on early mortality in gastric DLBCL by Wiedower, Eric, Chandler, Jason Claud, Pallera, Arnel M., Johnson, Robert Alan, Munene, Gitonga, Dickson, Paxton, Deneve, Jeremiah Lee, Fleming, Martin D., Tauer, Kurt W., Schwartzberg, Lee Steven, Martin, Michael Gary

“…Abstract only…”
Get full text

Serum and tumor biomarkers to predict outcome in the eLung trial, a multicenter, randomized phase IIb study of standard platinum doublets (PD) plus cetuximab (CET) as first-line treatment of advanced non-small cell lung cancer (NSCLC) by Miller, Paul J. E., Walker, Mark S., Tauer, Kurt W., Atkins, James, Sivarajan, Kulumani M, Patel, Vipul M., Bastos, Bruno R., Meyer, Krista, Roder, Joanna, Uyeda, Lisa, Salazar, Suzanne, Langer, Corey J., Socinski, Mark A., Spigel, David R., Schwartzberg, Lee Steven

“…Abstract only 8044 Background: The eLung trial randomized chemotherapy naïve advanced NSCLC patients (pts) to 1 of 3 PD and concurrent CET followed by CET…”
Get full text

Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial by Dillman, R O, Oldham, R K, Tauer, K W, Orr, D W, Barth, N M, Blumenschein, G, Arnold, J, Birch, R, West, W H

“…We conducted a multicenter, phase II trial of continuous-infusion recombinant interleukin-2 (rIL-2) and lymphokine-activated killer (LAK) cells. Patients had…”
Get more information

Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: Outpatient administration in community cancer centers by SCHWARTZBERG, L. S, BIRCH, R, GRECO, F. A, HAINSWORTH, J, RAEFSKY, E, BLANCO, R, BUCKNER, C. D, WEAVER, C. H, WEST, W. H, TAUER, K. W, WITTLIN, F, LEFF, R, CAMPOS, L, RYMER, W, CARTER, P, MANGUM, M

“…The authors determined outcomes for patients with localized high-risk breast cancer undergoing sequential outpatient treatment with conventional-dose adjuvant…”
Get full text

Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with five to nine involved axillary lymph nodes by SCHWARTZBERG, L. S, BIRCH, R, BUCKNER, C. D, WEAVER, C. H, TAUER, K. W, LEFF, R, GRECO, F. A, HAINSWORTH, J, RAEFSKY, E, MCANENY, B, WEAVER, Z, WEST, J

“…The purpose of this study is to determine outcomes for patients with high-risk nonmetastatic breast cancer undergoing high-dose chemotherapy with peripheral…”
Get full text

Immunotherapy of advanced cancer

Get more information

Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor by Schwartzberg, L S, Birch, R, Hazelton, B, Tauer, K W, Lee, Jr, P, Altemose, R, George, C, Blanco, R, Wittlin, F, Cohen, J

“…Chemotherapy can serve as a stimulus for mobilizing hematopoietic progenitor cells to the peripheral blood for harvest via leukapheresis. Mobilized peripheral…”
Get more information